Iterum Therapeutics


Novel oral carbapenem for the treatment of multi-drug resistant pathogens

Iterum is a clinical stage company developing a novel oral carbapenem, sulopenem, for the treatment of serious hospital and community-acquired infections including complicated urinary tract infections, uncomplicated urinary tract infections and complicated intra-abdominal infections.

CEO  Corey Fishman

Advent Contact  Shahzad Malik

Advent invested in the Series B round in 2017.
Publicly Listed